NO324521B1 - Anvendelse av sentrale cannabinoidreseptor-antagonister for fremstilling av legemidler som er anvendbare for a fremme stans av tobakksforbruk, farmasoytisk preparat, og sett. - Google Patents

Anvendelse av sentrale cannabinoidreseptor-antagonister for fremstilling av legemidler som er anvendbare for a fremme stans av tobakksforbruk, farmasoytisk preparat, og sett. Download PDF

Info

Publication number
NO324521B1
NO324521B1 NO20023765A NO20023765A NO324521B1 NO 324521 B1 NO324521 B1 NO 324521B1 NO 20023765 A NO20023765 A NO 20023765A NO 20023765 A NO20023765 A NO 20023765A NO 324521 B1 NO324521 B1 NO 324521B1
Authority
NO
Norway
Prior art keywords
nicotine
cessation
active principle
pharmaceutically acceptable
solvate
Prior art date
Application number
NO20023765A
Other languages
English (en)
Norwegian (no)
Other versions
NO20023765L (no
NO20023765D0 (no
Inventor
Jean Charles Blanchard
Francois Menard
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NO20023765D0 publication Critical patent/NO20023765D0/no
Publication of NO20023765L publication Critical patent/NO20023765L/no
Publication of NO324521B1 publication Critical patent/NO324521B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20023765A 2000-02-09 2002-08-08 Anvendelse av sentrale cannabinoidreseptor-antagonister for fremstilling av legemidler som er anvendbare for a fremme stans av tobakksforbruk, farmasoytisk preparat, og sett. NO324521B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0001682A FR2804604B1 (fr) 2000-02-09 2000-02-09 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
PCT/FR2001/000356 WO2001058450A2 (fr) 2000-02-09 2001-02-07 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Publications (3)

Publication Number Publication Date
NO20023765D0 NO20023765D0 (no) 2002-08-08
NO20023765L NO20023765L (no) 2002-10-09
NO324521B1 true NO324521B1 (no) 2007-11-12

Family

ID=8846875

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20023765A NO324521B1 (no) 2000-02-09 2002-08-08 Anvendelse av sentrale cannabinoidreseptor-antagonister for fremstilling av legemidler som er anvendbare for a fremme stans av tobakksforbruk, farmasoytisk preparat, og sett.

Country Status (32)

Country Link
US (2) US6930122B2 (sr)
EP (1) EP1257275B1 (sr)
JP (2) JP2003522145A (sr)
CN (1) CN1250220C (sr)
AR (1) AR028505A1 (sr)
AT (1) ATE292467T1 (sr)
AU (1) AU781827B2 (sr)
BG (2) BG110386A (sr)
BR (1) BR0108126A (sr)
CA (1) CA2397262C (sr)
CZ (1) CZ296685B6 (sr)
DE (1) DE60109903T2 (sr)
DK (1) DK1257275T3 (sr)
EE (1) EE04836B1 (sr)
ES (1) ES2240416T3 (sr)
FR (1) FR2804604B1 (sr)
HU (1) HU225328B1 (sr)
IL (1) IL150710A0 (sr)
IS (1) IS6450A (sr)
MX (1) MXPA02007766A (sr)
NO (1) NO324521B1 (sr)
NZ (1) NZ519924A (sr)
PL (1) PL201685B1 (sr)
PT (1) PT1257275E (sr)
RS (1) RS50404B (sr)
RU (1) RU2257207C2 (sr)
SI (1) SI1257275T1 (sr)
SK (1) SK284952B6 (sr)
TW (1) TWI243677B (sr)
UA (1) UA72783C2 (sr)
WO (1) WO2001058450A2 (sr)
ZA (1) ZA200205317B (sr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
US6462237B1 (en) * 2001-06-14 2002-10-08 Usv Limited Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
JP2005500690A (ja) 2001-08-13 2005-01-06 ハネウェル・インターナショナル・インコーポレーテッド オーバーレイヤーパターンを使用してウェハに担持された半導体デバイスの電流制御を提供すること
CA2478338A1 (en) 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
ATE486842T1 (de) 2002-03-12 2010-11-15 Merck Sharp & Dohme Substituierte amide
US7423067B2 (en) 2002-03-26 2008-09-09 Merck & Co., Inc. Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists
CA2479744A1 (en) 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
JP4459629B2 (ja) 2002-04-12 2010-04-28 メルク エンド カムパニー インコーポレーテッド 二環式アミド
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
US7091216B2 (en) 2002-08-02 2006-08-15 Merck & Co., Inc. Substituted furo[2,3-b]pyridine derivatives
EP1546115A4 (en) 2002-09-27 2010-08-04 Merck Sharp & Dohme Substituted pyrimidines
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
EP1575901B1 (en) 2002-12-19 2012-10-10 Merck Sharp & Dohme Corp. Substituted amides
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
EP1633733B1 (en) * 2003-05-20 2011-01-26 The University of Tennessee Research Foundation Cannabinoid derivatives, methods of making, and use thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
WO2005044785A1 (en) * 2003-10-30 2005-05-19 Merck & Co., Inc. Aralkyl amines as cannabinoid receptor modulators
WO2006025069A2 (en) 2004-07-12 2006-03-09 Cadila Healthcare Limited Tricyclic pyrazole derivatives as cannabinoid receptor modulators
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
WO2006060461A1 (en) 2004-12-03 2006-06-08 Schering Corporation Substituted piperazines as cb1 antagonists
BRPI0706623A2 (pt) * 2006-01-18 2011-04-12 Schering Corp moduladores de receptor canabinóide
CN101062919B (zh) * 2006-04-26 2012-08-15 中国人民解放军军事医学科学院毒物药物研究所 4-甲基-1h-二芳基吡唑衍生物及其作为药物的用途
WO2007121687A1 (en) * 2006-04-26 2007-11-01 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China 4-methyl-1h-diaryl pyrazole derivatives and their uses as medicament
US20070287734A1 (en) * 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
RU2455981C2 (ru) * 2006-06-16 2012-07-20 Теракос, Инк. Лечение ожирения антагонистами мускаринового рецептора м1
AU2007312233B2 (en) * 2006-10-20 2012-09-20 Abbvie B.V. Micellar nanoparticles of chemical substances
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
US20100286160A1 (en) * 2007-06-28 2010-11-11 Intervet Inc. Substituted piperazines as cb1 antagonists
EP2548874A3 (en) * 2007-06-28 2013-05-15 Intervet International B.V. Substituted piperazines as CB1 antagonists
EP2095814A1 (de) * 2008-02-26 2009-09-02 Wolfgang J. Kox Medikamentengestützter Nikotinentzug
JPWO2010018856A1 (ja) * 2008-08-13 2012-01-26 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
RU2533224C2 (ru) * 2010-07-21 2014-11-20 Мапикс Эс.Эй.Ар.Эл. Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения
WO2013068371A1 (en) 2011-11-08 2013-05-16 Intervet International B.V. Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists
WO2014181357A1 (en) * 2013-05-09 2014-11-13 Council Of Scientific & Industrial Research Novel pyrazole derivatives with silicon incorporation
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2765107B1 (fr) * 1997-06-26 2000-03-24 Sanofi Sa Utilisation d'un antagoniste specifique des recepteurs 5ht2 pour la preparation de medicaments utiles dans le traitement du syndrome d'apnee du sommeil
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Also Published As

Publication number Publication date
CN1250220C (zh) 2006-04-12
BG110386A (en) 2009-09-30
HUP0300237A2 (hu) 2003-07-28
PL358221A1 (en) 2004-08-09
DE60109903T2 (de) 2006-02-09
ES2240416T3 (es) 2005-10-16
EP1257275B1 (fr) 2005-04-06
NZ519924A (en) 2005-01-28
HK1051140A1 (en) 2003-07-25
SI1257275T1 (en) 2005-10-31
NO20023765L (no) 2002-10-09
US20050187253A1 (en) 2005-08-25
TWI243677B (en) 2005-11-21
RU2002118309A (ru) 2004-02-20
BR0108126A (pt) 2003-01-28
PT1257275E (pt) 2005-07-29
FR2804604B1 (fr) 2005-05-27
RS50404B (sr) 2009-12-31
DE60109903D1 (de) 2005-05-12
CA2397262C (en) 2007-09-11
UA72783C2 (en) 2005-04-15
HU225328B1 (en) 2006-09-28
AU3562001A (en) 2001-08-20
CZ296685B6 (cs) 2006-05-17
BG65856B1 (bg) 2010-03-31
IL150710A0 (en) 2003-02-12
YU59002A (sh) 2005-07-19
IS6450A (is) 2002-06-28
EE200200439A (et) 2003-12-15
DK1257275T3 (da) 2005-08-08
EE04836B1 (et) 2007-06-15
JP2010018622A (ja) 2010-01-28
WO2001058450A2 (fr) 2001-08-16
JP2003522145A (ja) 2003-07-22
SK11292002A3 (sk) 2003-02-04
US6930122B2 (en) 2005-08-16
US20030087933A1 (en) 2003-05-08
CN1406128A (zh) 2003-03-26
ATE292467T1 (de) 2005-04-15
ZA200205317B (en) 2003-09-04
NO20023765D0 (no) 2002-08-08
EP1257275A2 (fr) 2002-11-20
MXPA02007766A (es) 2002-10-11
CA2397262A1 (en) 2001-08-16
FR2804604A1 (fr) 2001-08-10
AR028505A1 (es) 2003-05-14
HUP0300237A3 (en) 2003-09-29
RU2257207C2 (ru) 2005-07-27
BG106946A (bg) 2003-05-30
AU781827B2 (en) 2005-06-16
CZ20022698A3 (cs) 2002-11-13
SK284952B6 (sk) 2006-03-02
WO2001058450A3 (fr) 2002-04-25
PL201685B1 (pl) 2009-04-30

Similar Documents

Publication Publication Date Title
AU781827B2 (en) Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation
CA2305799C (en) Composition for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug
RS59002B1 (sr) Pirimido[4,5-b]indol derivati i njihova primena u ekspanziji hematopoetskih matičnih ćelija
NO323696B1 (no) Anvendelse av sentrale cannabinoid-reseptor-antagonister for regulering av appetitt
EP2029139B1 (en) Use of a p38 kinase inhibitor for treating psychiatric disorders
JP2005506369A (ja) 肺高血圧症を予防または治療するのに用いられる医薬の製造のためのイルベサルタンの使用
HK1051140B (en) Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation
MXPA06008113A (en) Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist
MXPA00004989A (en) Method for combating obesity

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees